This project will mainly focus on Middle and old-aged adults, and examine whether Cardiovascular and metabolic risks can be reduced. In the meanwhile, this project will develop strategies for improving muscle loss , muscle strength decline, and the quality life of the elderly.
Cardiovascular diseases are common among the elder. However, previous researches mainly focus on observational research or small scale clinical trial, and the subjects are mainly youth. Therefore, this project hope to understand whether Oligonol can reduce Cardiovascular and metabolic risks among senior adults. Consequently,improve muscle loss muscle strength decline, quality of old adults life. This project design may potentially develop new strategies for curing Sarcopenia as well.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
120
Major intervention of Oligonol component , as suggested Oligonol safe dose for adults is 200mg per day.
Placebo
Taipei Veteran General Hospital
Taipei, Taiwan
Changes from baseline muscle after 12 weeks
Change from baseline muscle via MRI after 12 weeks.
Time frame: baseline,12 weeks
Changes from baseline fat content of leg after 12 weeks
Change from baseline fat content of leg via MRI after 12 weeks.
Time frame: baseline,12 weeks
Changes form baseline chair-stand after 12 weeks
measured by the time of chair-stand after 12 weeks.
Time frame: baseline, 12 weeks
Changes form baseline muscle strength after 12 weeks
measured by hand grip distance after 12 weeks.
Time frame: baseline, 12 weeks
Change from baseline Nutrition intake after 12 weeks
measured by Mini-nutritional assessment questionnaire. ranged 0-30, higher values represent a better condition
Time frame: baseline, 12 weeks
Change from baseline depression after 12 weeks
measured by the Center for Epidemiological Studies-Depression (CES-D) ranged 0-60, higher values represent a worse condition
Time frame: baseline, 12 weeks
Change from baseline endurance after 12 weeks
measured by 6-minute walk distance
Time frame: baseline, 12 weeks
Change from baseline walking speed after 12 weeks
measured by six-meter walking speed
Time frame: baseline, 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change from baseline timed up and go test after 12 weeks
measured by timed up and go test (TUG)
Time frame: baseline, 12 weeks
Change from baseline numbers of Complete blood count after 12 weeks
Change from baseline numbers of Complete blood count after 12 weeks
Time frame: baseline,12 weeks
Change from baseline concentration of Albumin after 12 weeks
Change from baseline concentration of Albumin after 12 weeks
Time frame: baseline,12 weeks
Change from baseline concentration of Alanine Aminotransferase (ALT) after 12 weeks.
Change from baseline concentration of Alanine Aminotransferase (ALT) after 12 weeks.
Time frame: baseline,12 weeks
Change from baseline concentration of Aspartate Aminotransferase (AST) after 12 weeks.
Change from baseline concentration of Aspartate Aminotransferase (AST) after 12 weeks.
Time frame: baseline,12 weeks
Change from baseline concentration of blood urea nitrogen after 12 weeks
Change from baseline concentration of blood urea nitrogen after 12 weeks
Time frame: baseline,12 weeks
Change from baseline concentration of Creatinin after 12 weeks
Change from baseline concentration of Creatinin after 12 weeks
Time frame: baseline,12 weeks
Change from baseline concentration of Fasting glucose after 12 weeks
Change from baseline concentration of Fasting glucose after 12 weeks
Time frame: baseline,12 weeks
Change from baseline concentration of Total Cholesterol after 12 weeks
Change from baseline concentration of Total Cholesterol after 12 weeks
Time frame: baseline,12 weeks
Change from baseline concentration of Triglyceride after 12 weeks
Change from baseline concentration of Triglyceride after 12 weeks
Time frame: baseline,12 weeks
Change from baseline concentration of high-density lipoprotein cholesterol after 12 weeks
Change from baseline concentration of high-density lipoprotein cholesterol after 12 weeks
Time frame: baseline,12 weeks
Change from baseline concentration of low-density lipoprotein cholesterol after 12 weeks
Change from baseline concentration of low-density lipoprotein cholesterol after 12 weeks
Time frame: baseline,12 weeks
Change from baseline concentration of high-sensitivity C-reactive protein after 12 weeks
Change from baseline concentration of high-sensitivity C-reactive protein after 12 weeks
Time frame: baseline,12 weeks
Change from baseline concentration of dehydroepiandrosterone after 12 weeks
Change from baseline concentration of dehydroepiandrosterone after 12 weeks
Time frame: baseline,12 weeks
Change from baseline concentration of 25-(OH)-Vit. D after 12 weeks
Change from baseline concentration of 25-(OH)-Vit. D after 12 weeks
Time frame: baseline,12 weeks
Change from baseline concentration of Leptin after 12 weeks
Change from baseline concentration of 25-(OH)-Vit. D after 12 weeks
Time frame: baseline,12 weeks
Change from baseline concentration of urine protein after 12 weeks
Change from baseline concentration of urine protein after 12 weeks
Time frame: baseline,12 weeks